LymeNet Home LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Menu

LymeNet on Facebook

LymeNet on Twitter

The Lyme Disease Network receives a commission from for each purchase originating from this site.

When purchasing from, please
click here first.

Thank you.

LymeNet Flash Discussion
Dedicated to the Bachmann Family

LymeNet needs your help:
LymeNet 2020 fund drive

The Lyme Disease Network is a non-profit organization funded by individual donations.

LymeNet Flash Post New Topic  New Poll  Post A Reply
my profile | directory login | register | search | faq | forum home

  next oldest topic   next newest topic
» LymeNet Flash » Questions and Discussion » Medical Questions » GlaxoSmithKline and Mpex developing new abx with efflux pump inhibitors

 - UBBFriend: Email this page to someone!    
Author Topic: GlaxoSmithKline and Mpex developing new abx with efflux pump inhibitors
LymeNet Contributor
Member # 9405

Icon 1 posted      Profile for ldfighter     Send New Private Message       Edit/Delete Post   Reply With Quote 
Possible abx/efflux pump inhibitor combos in development. (research) (June 16, 2008 press release below)

GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections

Potential to combine compounds with multiple new and existing antibiotics to create a broad offering of anti-infective medicines with activity against drug-resistant organisms

San Diego, California, and London, UK - June 16th, 2008 - Mpex Pharmaceuticals and GlaxoSmithKline (GSK) today announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialization of novel medicines for bacterial diseases.

The collaboration provides GlaxoSmithKline access to Mpex's novel efflux pump inhibitors (EPI) and related proprietary technology for use in combination with a variety of antibiotics. The collaboration will focus on the discovery and development of novel drug regimens comprising Mpex's EPIs combined with GSK's novel development stage compounds as well as existing commercial antibiotics to improve potency and broaden the spectrum of antibacterial activity.

Under the terms of the agreement, Mpex will grant GlaxoSmithKline rights to product candidates developed under the collaboration that are directed to three different target product profiles and with the potential to deliver up to seven treatment options.

Mpex will be responsible for the discovery of EPI drug candidates and the development of combination product candidates through clinical proof of concept, at which point GlaxoSmithKline will have an option to exclusively license each product candidate for further development and commercialization on a worldwide basis. Mpex will retain the right to further develop and commercialize product candidates for which GlaxoSmithKline does not exercise its option... GlaxoSmithKline will participate in the alliance through its Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD).

"We believe this collaboration has the potential to lead to a number of important new anti-infective products," said Daniel Burgess, President and CEO of Mpex Pharmaceuticals. "The critical role of antibiotic efflux has been well recognized in bacterial resistance, but to date, safe and effective efflux pump inhibitors have not been developed. Given the progress Mpex has made in this program over the last several years, we are optimistic that combining our efforts with an industry leader such as GlaxoSmithKline will maximize our chances of success to develop a portfolio of products from this platform technology that is greater than we could hope to develop on our own. In addition, GlaxoSmithKline has an impressive array of novel new classes of antibiotics in development, and we believe that a number of these antibiotic opportunities could benefit from the addition of an Mpex efflux pump inhibitor."

"Antibiotic discovery has faced tremendous challenges with the discovery of only two new classes of antibiotics over the last 3 decades," stated Zhi Hong, Senior Vice President of the ID CEDD at GlaxoSmithKline. "Novel discovery-enabling and paradigm-shifting approaches are needed to address the ever increasing medical needs due to life-threatening bacterial infections and drug resistance. Efflux pump inhibitors have the potential to add value to existing antibiotics and also enable progressive development of GSK's novel antibiotic pipeline. Mpex has a first rate entrepreneurial R&D team with deep experience in antibacterial research and has validated efflux pump inhibition for potentiation of antibacterial activity, as well as expanding the spectrum of bacterial susceptibility. I look forward to having a great synergy in this important and strategic collaboration."

Bacterial efflux pumps are an intrinsic defense mechanism in gram-negative bacteria that expel toxins such as antibiotics that have permeated the outer cell membrane before they can reach their targets and kill the bacteria. Higher intracellular antibiotic concentrations achieved through efflux pump inhibition can increase the potency and pharmacological barrier against other drug resistance mechanisms (e.g., target-based mutations).

There are currently no drugs approved to inhibit the activity of these efflux pumps and restore the potency of otherwise effective antibiotics. Mpex has been a leader in this field of research for a number of years and has identified several series of lead EPIs that are now being optimized for development. These compounds have been shown in both in vitro and in vivo pre-clinical studies to significantly improve the potency of a number of different antibiotic classes against drug-resistant gram-negative pathogens, including Pseudomonas aeruginosa and Klebsiella pneumoniae.

Posts: 621 | From US | Registered: Jun 2006  |  IP: Logged | Report this post to a Moderator
LymeNet Contributor
Member # 7964

Icon 1 posted      Profile for jjeennnniiee     Send New Private Message       Edit/Delete Post   Reply With Quote 
Up for you, jamescase, since I know you'll be interested in seeing this! [Smile]

Love, Light, & Health,

My Lyme dx:11/05. My Mom's Lyme dx:5/16. ISO ASAP-Lyme Literate Dr & Neurologist-Prefer IL, IN, KY, MO, OH, TN. Can travel farther. Finances limited. Prefer Drs take Medicare or Payments. Need great list to find best fit. Tyvm.

Posts: 701 | From Owensboro, KY | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Frequent Contributor (1K+ posts)
Member # 8165

Icon 1 posted      Profile for cantgiveupyet     Send New Private Message       Edit/Delete Post   Reply With Quote 
wonder if this is what my llmd was talking about.

these would make for one heck of a herx.

"Say it straight simple and with a smile."

"Thus the task is, not so much to see what no one has seen yet,
But to think what nobody has thought yet, About what everybody sees."


pos babs, bart, igenex WB igm/igg

Posts: 3156 | From Lyme limbo | Registered: Oct 2005  |  IP: Logged | Report this post to a Moderator

Quick Reply

HTML is not enabled.
UBB Code is enabled.

Instant Graemlins

Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:

Contact Us | LymeNet home page | Privacy Statement

Powered by UBB.classic™ 6.7.3

The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:

The Lyme Disease Network of New Jersey
907 Pebble Creek Court, Pennington, NJ 08534 USA

| Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet | Contact Us

© 1993-2020 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to Terms and Conditions.